Editas Medicine (EDIT) Short Interest Ratio & Short Volume $2.10 +0.17 (+8.81%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$2.12 +0.02 (+1.19%) As of 06/10/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Editas Medicine Short Interest DataEditas Medicine (EDIT) has a short interest of 9.09 million shares, representing 11.22% of the float (the number of shares available for trading by the public). This marks a -21.71% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.9, indicating that it would take 3.9 days of the average trading volume of 2.57 million shares to cover all short positions.Current Short Interest9,090,000 sharesPrevious Short Interest11,610,000 sharesChange Vs. Previous Month-21.71%Dollar Volume Sold Short$12.68 millionShort Interest Ratio3.9 Days to CoverLast Record DateMay 15, 2025Outstanding Shares83,713,000 sharesShort Percent of Float11.22%Today's Trading Volume2,877,174 sharesAverage Trading Volume2,573,345 sharesToday's Volume Vs. Average112% Short Selling Editas Medicine? Sign up to receive the latest short interest report for Editas Medicine and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEDIT Short Interest Over TimeEDIT Days to Cover Over TimeEDIT Percentage of Float Shorted Over Time Editas Medicine Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20259,090,000 shares $12.68 million -21.7%11.2%3.9 $1.40 4/30/202511,610,000 shares $19.16 million -8.4%N/A3.2 $1.65 4/15/202512,670,000 shares $17.10 million -0.1%15.6%3.5 $1.35 3/31/202512,680,000 shares $14.71 million -3.6%15.7%3.3 $1.16 3/15/202513,150,000 shares $19.20 million -4.5%16.2%3.4 $1.46 2/28/202513,770,000 shares $26.44 million -21.0%17.0%3.3 $1.92 2/15/202517,440,000 shares $24.07 million +2.1%21.5%4.4 $1.38 1/31/202517,090,000 shares $22.39 million -10.8%N/A6.6 $1.31 1/15/202519,150,000 shares $23.36 million +5.2%N/A7.1 $1.22 12/31/202418,210,000 shares $23.13 million +7.6%N/A7 $1.27 Get the Latest News and Ratings for EDIT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 12/15/202416,930,000 shares $24.38 million +5.4%N/A6.9 $1.44 11/30/202416,060,000 shares $35.97 million +0.9%N/A7.2 $2.24 11/15/202415,910,000 shares $42.32 million -7.7%N/A7.4 $2.66 10/31/202417,240,000 shares $50.00 million -6.0%N/A8.8 $2.90 10/15/202418,330,000 shares $61.59 million +9.5%N/A9.9 $3.36 9/30/202416,740,000 shares $57.08 million -11.7%N/A9.3 $3.41 9/15/202418,960,000 shares $74.89 million +5.3%N/A10.5 $3.95 8/31/202418,010,000 shares $67.36 million +6.6%N/A9.4 $3.74 8/15/202416,900,000 shares $67.60 million +4.8%N/A8.5 $4.00 7/31/202416,130,000 shares $87.26 million +2.2%N/A7.7 $5.41 7/15/202415,790,000 shares $88.58 million -5.7%N/A7.6 $5.61 6/30/202416,740,000 shares $78.18 million -22.9%N/A8 $4.67 6/15/202421,700,000 shares $109.80 million -1.5%N/A10.6 $5.06 5/31/202422,020,000 shares $114.50 million +6.1%N/A11.7 $5.20 5/15/202420,760,000 shares $124.56 million +1.3%N/A10.3 $6.00 4/30/202420,500,000 shares $106.81 million +9.3%N/A10.3 $5.21 4/15/202418,760,000 shares $114.06 million +14.7%N/A9.8 $6.08 3/31/202416,360,000 shares $121.39 million +17.4%N/A8.9 $7.42 3/15/202413,930,000 shares $113.25 million +3.0%N/A7.5 $8.13 2/29/202413,520,000 shares $136.01 million +7.4%N/A7 $10.06 2/15/202412,590,000 shares $104.62 million +3.1%N/A7.2 $8.31 1/31/202412,210,000 shares $85.84 million -2.2%N/A6.7 $7.03 1/15/202412,480,000 shares $113.19 million -2.4%N/A6.8 $9.07 12/31/202312,790,000 shares $129.56 million -14.6%N/A7 $10.13 12/15/202314,970,000 shares $163.62 million -5.1%N/A7.7 $10.93 11/30/202315,780,000 shares $166.16 million -0.6%N/A8.9 $10.53 11/15/202315,870,000 shares $140.29 million -5.4%N/A9.7 $8.84 10/31/202316,770,000 shares $112.02 million +2.1%N/A11 $6.68 10/15/202316,420,000 shares $115.76 million +2.8%N/A11.2 $7.05 9/30/202315,970,000 shares $124.57 million +5.2%N/A11.1 $7.80The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 9/15/202315,180,000 shares $127.36 million +4.7%N/A10.8 $8.39 8/31/202314,500,000 shares $129.20 million +0.6%N/A8.1 $8.91 8/15/202314,410,000 shares $126.23 million -6.7%N/A7.5 $8.76 7/31/202315,440,000 shares $135.56 million -0.2%N/A7.5 $8.78 7/15/202315,470,000 shares $133.20 million -20.4%N/A7.4 $8.61 6/30/202319,430,000 shares $159.91 million -5.8%N/A8.6 $8.23 6/15/202320,630,000 shares $191.45 million +0.6%N/A9 $9.28 5/31/202320,500,000 shares $188.19 million +1.3%N/A11 $9.18 5/15/202320,230,000 shares $202.50 million +7.3%N/A11 $10.01 4/30/202318,860,000 shares $153.90 million -5.5%N/A10.7 $8.16 4/15/202319,950,000 shares $151.42 million +1.5%N/A11.1 $7.59 3/31/202319,650,000 shares $142.46 million -4.8%N/A11.3 $7.25 3/15/202320,640,000 shares $174.00 million +7.7%N/A11.9 $8.43 2/28/202319,160,000 shares $173.21 million -2.6%N/A10 $9.04 2/15/202319,670,000 shares $203.78 million -6.1%N/A10.2 $10.36 1/31/202320,940,000 shares $207.10 million -5.4%N/A10.5 $9.89 1/15/202322,140,000 shares $186.64 million +2.3%N/A11.8 $8.43 12/30/202221,650,000 shares $192.04 million +2.3%N/A12 $8.87 12/15/202221,170,000 shares $211.91 million +7.7%N/A12.3 $10.01 11/30/202219,650,000 shares $208.29 million +4.0%N/A11.7 $10.60 11/15/202218,900,000 shares $246.65 million +2.3%N/A12.1 $13.05 10/31/202218,470,000 shares $231.80 million -0.4%N/A12.1 $12.55 10/15/202218,540,000 shares $210.99 million +2.2%N/A11.8 $11.38 9/30/202218,150,000 shares $222.16 million +5.3%N/A11 $12.24 9/15/202217,240,000 shares $277.74 million +3.4%N/A10.1 $16.11 8/31/202216,680,000 shares $245.20 million +2.7%N/A9.6 $14.70 8/15/202216,250,000 shares $299.98 million -3.1%N/A9.3 $18.46 7/31/202216,770,000 shares $266.81 million +2.4%N/A9.5 $15.91 7/15/202216,380,000 shares $245.54 million +7.0%N/A9.3 $14.99 6/30/202215,310,000 shares $181.12 million +4.7%N/A9 $11.83 6/15/202214,620,000 shares $153.95 million +1.3%N/A8.8 $10.53 5/31/202214,430,000 shares $164.36 million +10.2%N/A9.1 $11.39 5/15/202213,090,000 shares $155.38 million +3.7%N/A7.7 $11.87 4/30/202212,620,000 shares $167.09 million +0.9%N/A7.3 $13.24 4/15/202212,510,000 shares $208.54 million +1.8%N/A6.9 $16.67 3/31/202212,290,000 shares $233.76 million +4.0%N/A6.5 $19.02 3/15/202211,820,000 shares $176.24 million +3.2%N/A6.3 $14.91 2/28/202211,450,000 shares $196.02 million +3.1%N/A6.1 $17.12 2/15/202211,110,000 shares $184.98 million +1.3%N/A6.1 $16.65 1/31/202210,970,000 shares $208.87 million -3.2%N/A6.5 $19.04 1/15/202211,330,000 shares $250.39 million -0.6%N/A7.8 $22.10 12/31/202111,400,000 shares $302.67 million +5.3%N/A8.8 $26.55 12/15/202110,830,000 shares $324.25 million +9.7%N/A6.9 $29.94 11/30/20219,870,000 shares $322.35 million +3.5%N/A6.7 $32.66 11/15/20219,540,000 shares $343.34 million -4.3%N/A6.4 $35.99 10/29/20219,970,000 shares $366.10 million -1.9%N/A6 $36.72 10/15/202110,160,000 shares $386.28 million +47.3%N/A5.8 $38.02 9/30/20216,900,000 shares $283.45 million -1.4%N/A3.9 $41.08 9/15/20217,000,000 shares $422.10 million +3.4%N/A3.5 $60.30 8/31/20216,770,000 shares $430.50 million -9.7%N/A3.5 $63.59The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 8/13/20217,500,000 shares $469.95 million -11.7%N/A4 $62.66 7/30/20218,490,000 shares $355.39 million +1.9%N/A4.7 $41.86 7/15/20218,330,000 shares $349.78 million -20.1%12.3%5 $41.99 6/30/202110,430,000 shares $590.76 million +0.6%15.4%5.9 $56.64 6/15/202110,370,000 shares $363.99 million -2.4%15.3%8 $35.10 5/28/202110,620,000 shares $360.55 million +0.9%15.7%7.9 $33.95 5/14/202110,530,000 shares $330.64 million +1.0%N/A6.2 $31.40 4/30/202110,430,000 shares $389.77 million +1.8%N/A5.3 $37.37 4/15/202110,250,000 shares $425.68 million +0.4%N/A4.7 $41.53 3/31/202110,210,000 shares $413.51 million -3.8%N/A4.1 $40.50 3/15/202110,610,000 shares $491.03 million -6.2%N/A3.7 $46.28 2/26/202111,310,000 shares $506.24 million +14.9%N/A3.5 $44.76 2/12/20219,840,000 shares $562.55 million +9.1%N/A3.3 $57.17 1/29/20219,020,000 shares $551.39 million -5.1%N/A3.4 $61.13 1/15/20219,500,000 shares $721.24 million -3.9%N/A3.9 $75.92 12/31/20209,890,000 shares $756.59 million -9.2%N/A4.8 $76.50 12/15/202010,890,000 shares $669.63 million -1.5%N/A6.4 $61.49 11/30/202011,060,000 shares $346.62 million -1.7%N/A10.2 $31.34 11/15/202011,250,000 shares $328.84 million -0.4%N/A12.9 $29.23 10/30/202011,290,000 shares $370.26 million -0.1%N/A13.6 $32.80 10/15/202011,300,000 shares $363.41 million +7.9%N/A12.7 $32.16 9/30/202010,470,000 shares $293.79 million +7.5%N/A11.9 $28.06 9/15/20209,740,000 shares $310.71 million +6.2%N/A9.7 $31.90 8/31/20209,170,000 shares $323.06 million -0.7%N/A8.5 $35.23 8/14/20209,230,000 shares $322.31 million +4.5%N/A8.5 $34.92 7/31/20208,830,000 shares $259.25 million -0.5%N/A7.7 $29.36 7/15/20208,870,000 shares $289.34 million -5.6%N/A8.2 $32.62 6/30/20209,400,000 shares $278.05 million +3.5%N/A9 $29.58 6/15/20209,080,000 shares $262.78 million +9.3%N/A9.2 $28.94 EDIT Short Interest - Frequently Asked Questions What is Editas Medicine's current short interest? Short interest is the volume of Editas Medicine shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 9,090,000 shares of EDIT short. 11.22% of Editas Medicine's shares are currently sold short. Learn More on Editas Medicine's current short interest. What is a good short interest ratio for Editas Medicine? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EDIT shares currently have a short interest ratio of 4.0. Learn More on Editas Medicine's short interest ratio. Which institutional investors are shorting Editas Medicine? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Editas Medicine: Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Editas Medicine? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.22% of Editas Medicine's floating shares are currently sold short. Is Editas Medicine's short interest increasing or decreasing? Editas Medicine saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 9,090,000 shares, a decrease of 21.7% from the previous total of 11,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Editas Medicine's short interest compare to its competitors? 11.22% of Editas Medicine's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Editas Medicine: Taysha Gene Therapies, Inc. (13.16%), Iovance Biotherapeutics, Inc. (28.36%), Trevi Therapeutics, Inc. (11.82%), Keros Therapeutics, Inc. (18.48%), Stoke Therapeutics, Inc. (24.84%), Mind Medicine (MindMed) Inc. (15.79%), Bicycle Therapeutics plc (5.27%), Dianthus Therapeutics, Inc. (28.57%), Relay Therapeutics, Inc. (14.46%), Maravai LifeSciences Holdings, Inc. (5.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Editas Medicine stock? Short selling EDIT is an investing strategy that aims to generate trading profit from Editas Medicine as its price is falling. EDIT shares are trading up $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Editas Medicine? A short squeeze for Editas Medicine occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EDIT, which in turn drives the price of the stock up even further. How often is Editas Medicine's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EDIT, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies Taysha Gene Therapies Short Squeeze Iovance Biotherapeutics Short Squeeze Trevi Therapeutics Short Squeeze Keros Therapeutics Short Squeeze Stoke Therapeutics Short Squeeze Mind Medicine (MindMed) Short Squeeze Bicycle Therapeutics Short Squeeze Dianthus Therapeutics Short Squeeze Relay Therapeutics Short Squeeze Maravai LifeSciences Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EDIT) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts